Clinical Trial Search

Primary: Incidence and Severity of Observed or Self-reported Adverse Events (AEs) Considered PfSPZ-DVI Challenge Inoculum-related. — 13; 12; 1; 2 Incidence

Primary: Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a Standardized Approach — 234.5 Ratio

Primary: Percentage of Participants With Parasite Clearance at Day 28 — 97.20 percentage of participants

Primary: Successful Infection of Vector Mosquitoes Following Both Direct and Indirect Feeding on the Blood of Infected Participants

Primary: Minimum Inhibitory Concentration (MIC) and Minimum Parasiticidal Concentration (MPC) — 2.4; 4.1; 77; 319 ng/Ml

Primary: Derived Parasite Reduction Rate at 24 Hours (PPR24) — 1.38; 1.56; 1.71; 1.63 Log10 parasites/24h — p=0.01

Primary: Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 28 (ACPR28) — 80.8; 90.3; 90.9…

Primary: Infection Rate — 5; 6; 3; 0 Participants

Primary: Absence of Malaria Parasites in Blood. — 73 Participants

Primary: Emax — 0.201 Maximum clearance rate (1/hour)

Primary: The Activity of Single Oral Doses of MMV533 (Name of Investigational Medicinal Product) on Clearance of Plasmodium — 42.17; 158.03; 187.57 PRR48=parasite reduction ratio…

Primary: Characterize the PK/PD Relationship Between OZ439 and PQP Plasma Concentrations (Cmax) — 0.2582; 0.4145; 0.8829; 0.6835 ng/L

Primary: Early Treatment Failure (ETF) — 0; 0 participants

Primary: Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28 — 99.2; 98.1 percentage of subjects — p=0.106

Primary: PCR-Corrected ACPR at Day 28 — 95; 99; 99 percentage of subjects

Primary: Cure Rates of AQ-13 and Coartem for Uncomplicated Plasmodium Falciparum Malaria in Adult Malian Males. — 28; 31 Participants

Primary: Cohort A: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Related TEAEs — 9; 0; 1 Participants

Primary: Malaria Diagnosis Using RealAmp and Microscopy. — 42; 153; 0; 1 Participants

Primary: Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Infants and Children (<5 Years) in Post Community…

Primary: Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled — 61; 88; 90 participants

Primary: PCR-adjusted ACPR at Day 28 in the PP Population (All Patients) — 70.8; 68.4; 78.6 % ACPR PCR-adjusted

Primary: Percentage of Patients With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28 — 11; 13; 15; 14 Participants

Primary: Emax — 0.35 Maximum clearance rate (1/hour)

Primary: Individual Parasite Reduction Ratio (PRR) — 1132; 217646; 314040; 8021 none (ratio)

Primary: Time to Parasite Clearance — 23.63; 44.97; 48.75 Hours

Primary: Time to Parasitemia Since Negative Blood Smear After Treatment — 62.0; 60.0; NA; NA days

Primary: PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) Rate on Day 28 — 99.5; 99.2 percentage of subjects — p=0.578

Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation of Study Treatment — 13; 6; 5; 3…

Primary: Prevalence of Placental Malaria — 49; 30; 26 Participants

Primary: Infection Success of Vector Mosquitoes — 2; 3 Participants